% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Denkinger:186515,
      author       = {C. M. Denkinger and M. Janssen and U. Schäkel and J. Gall
                      and A. Leo and P. Stelmach and S. F. Weber and J. Krisam and
                      L. Baumann and J. Stermann and U. Merle and M. A. Weigand
                      and C. Nusshag and L. Bullinger and J.-F. Schrezenmeier and
                      M. Bornhäuser and N. Alakel and O. Witzke and T. Wolf and
                      M. J. G. T. Vehreschild and S. Schmiedel and M. M. Addo and
                      F. Herth and M. Kreuter and P.-R. Tepasse and B. Hertenstein
                      and M. Hänel and A. Morgner and M. Kiehl and O. Hopfer and
                      M.-A. Wattad and C. C. Schimanski and C. Celik and T. Pohle
                      and M. Ruhe and W. V. Kern and A. Schmitt and H.-M. Lorenz
                      and M. Souto-Carneiro and M. Gaeddert and N. Halama$^*$ and
                      S. Meuer and H.-G. Kräusslich and B. Müller and P.
                      Schnitzler and S. Parthé and R. Bartenschlager and M.
                      Gronkowski and J. Klemmer and M. Schmitt and P. Dreger and
                      K. Kriegsmann and R. F. Schlenk and C. Müller-Tidow},
      title        = {{A}nti-{SARS}-{C}o{V}-2 antibody-containing plasma improves
                      outcome in patients with hematologic or solid cancer and
                      severe {COVID}-19: a randomized clinical trial.},
      journal      = {Nature cancer},
      volume       = {4},
      number       = {1},
      issn         = {2662-1347},
      address      = {London},
      publisher    = {Nature Research},
      reportid     = {DKFZ-2022-03217},
      pages        = {96-107},
      year         = {2023},
      note         = {2023 Jan;4(1):96-107 / HI-TRON},
      abstract     = {Patients with cancer are at high risk of severe coronavirus
                      disease 2019 (COVID-19), with high morbidity and mortality.
                      Furthermore, impaired humoral response renders severe acute
                      respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines
                      less effective and treatment options are scarce. Randomized
                      trials using convalescent plasma are missing for high-risk
                      patients. Here, we performed a randomized, open-label,
                      multicenter trial (
                      https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001632-10/DE
                      ) in hospitalized patients with severe COVID-19 (n = 134)
                      within four risk groups ((1) cancer (n = 56); (2)
                      immunosuppression (n = 16); (3) laboratory-based risk
                      factors (n = 36); and (4) advanced age (n = 26)) randomized
                      to standard of care (control arm) or standard of care plus
                      convalescent/vaccinated anti-SARS-CoV-2 plasma (plasma arm).
                      No serious adverse events were observed related to the
                      plasma treatment. Clinical improvement as the primary
                      outcome was assessed using a seven-point ordinal scale.
                      Secondary outcomes were time to discharge and overall
                      survival. For the four groups combined, those receiving
                      plasma did not improve clinically compared with those in the
                      control arm (hazard ratio (HR) = 1.29; P = 0.205). However,
                      patients with cancer experienced a shortened median time to
                      improvement (HR = 2.50; P = 0.003) and superior survival
                      with plasma treatment versus the control arm (HR = 0.28; P =
                      0.042). Neutralizing antibody activity increased in the
                      plasma cohort but not in the control cohort of patients with
                      cancer (P = 0.001). Taken together, convalescent/vaccinated
                      plasma may improve COVID-19 outcomes in patients with cancer
                      who are unable to intrinsically generate an adequate immune
                      response.},
      cin          = {D240},
      ddc          = {610},
      cid          = {I:(DE-He78)D240-20160331},
      pnm          = {314 - Immunologie und Krebs (POF4-314)},
      pid          = {G:(DE-HGF)POF4-314},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:36581734},
      doi          = {10.1038/s43018-022-00503-w},
      url          = {https://inrepo02.dkfz.de/record/186515},
}